Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients.

CONCLUSION: Urinary PCA3 is a useful test with high diagnostic performances for early prostate cancer diagnosis. Its correlation with cancer aggressiveness seems rather represented by a link to prostate volume than Gleason score. LEVEL OF EVIDENCE: 5. PMID: 26586639 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research

Related Links:

Publication date: Available online 17 September 2019Source: Pathology - Research and PracticeAuthor(s): Yoo Jin Lee, Harim Oh, Eojin Kim, Bokyung Ahn, Jeong Hyeon Lee, Youngseok Lee, Yang Seok Chae, Sung Gu Kang, Chul Hwan KimAbstractHOXA transcript at the distal tip (HOTTIP) is a long noncoding RNA (lncRNA), which is>200 nucleotides in length. HOTTIP expression has been demonstrated to play a crucial oncogenic role in cancer pathogenesis, and is said to be associated with poor human cancer prognosis. In prostate cancer, HOTTIP has been identified as an oncogene, but its clinicopathologic significance remains unclear. A...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Oncology News Burst
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
This study aims to investigate the antiproliferative activity and potential mechanism of action of the xanthoquinodin JBIR-99, isolated from fungi Parengyodontium album MEXU 30,054 and identified by single-crystal X-ray crystallography. Cytotoxicity of xanthoquinodin was evaluated in a panel of human cancer cells lines and CCD-112-CoN normal colon cells, using the sulforhodamine B assay. PC-3 prostate cancer cells were used in biochemical assays including cell cycle, mitochondrial transmembrane potential (MTP), reactive oxygen species (ROS) and caspase activity. Expression levels of apoptosis-pathway-related proteins were ...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
A $35 million gift from Salesforce.com Inc. co-founder and co-CEO Marc Benioff and his wife Lynne targets research in prostate cancer, which killed Marc Benioff's father in 2012. The gift is the latest in a succession of philanthropy from the Benioffs to UCSF, most notably the largest gift behind construction of UCSF Benioff Children's Hospital in Mission Bay and the ongoing work at UCSF Benioff Children's Hospital Oakland. Most recently, the couple gave $35 million last m onth to UCSF and Stanford…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The study was published Sept. 18 in the journal Cell Communication and Signaling.
Source: SUNY Upstate Medical - Category: Universities & Medical Training Source Type: news
Condition:   Prostatic Neoplasms Interventions:   Procedure: Radical Prostatectomy;   Other: Radical Radiotherapy Sponsors:   Tongji Hospital;   Changhai Hospital;   Zhejiang University;   Sun Yat-sen University;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   Tianjin Medical University Second Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Localized prostate cancer (PCa) has a high cure rate of 95.5%. PCa patients receive radiation therapy (RT) as a standard of care treatment. However, the major concern is the treatment-related side effects compromising the quality of life (QoL) in PCa patients. Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible late side effect of RT, that develops in more than half of PCa patients. There is no FDA approved drug to treat RiED. Phosphodiesterase type 5 inhibitors (PDE5i) are the most common pharmacological agents being used to treat RiED.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Mounting evidence supports complete metastatic ablation for oligometastatic cancer but the relevance of this approach to oligometastatic prostate cancer (OMPC) remain an area of active study. Importantly, biomarkers to determine patients who benefit most from complete ablation are unknown. We hypothesize that stereotactic ablative radiation (SABR) will improve oncologic outcomes in men with OMPC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Salvage radiation therapy (SRT) is recommended for men with biochemically recurrent prostate cancer post-radical prostatectomy. RTOG 9601 was a randomized phase 3 clinical trial that demonstrated an overall survival (OS) benefit from the addition of long-term anti-androgen therapy to SRT. However, hormone therapy has well documented side effects and has been shown to increase cardiac event rates, and there remains no evidence of an OS benefit from hormone therapy for men treated with early SRT. Herein, we aim to determine if pre-SRT PSA can serve as both a prognostic and predictive biomarker of benefit or harm from hormone therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Healthcare systems are often compared with the aviation industry. Progress in both is highly desired but must always be achieved with safety in mind. Everyone wants to get from point A to point B faster and more comfortably, but how much risk of uncertainty is one ready to accept to achieve that extra speed? Both industries also share the aspect of competition for customers. In the field of localized prostate cancer, patients have an ever-increasing choice of options: radical surgery (open vs laparoscopic vs robot-assisted), external beam radiation therapy (EBRT) (with photons or protons), brachytherapy (low-dose rate or h...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Urology & Nephrology